Investing.com - Century Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Century Therapeutics announced earnings per share of $-0.53 on revenue of $2.22M. Analysts polled by Investing.com anticipated EPS of $-0.59 on revenue of $1.06M.
Century Therapeutics shares are down 4.96% from the beginning of the year and are trading at $11.58 , down-from-52-week-high.
Century Therapeutics shares gained 15.11% in intra-day trade following the report.
Century Therapeutics follows other major Healthcare sector earnings this month
Century Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar